Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i

J Hematother Stem Cell Res. 2002 Aug;11(4):719-30. doi: 10.1089/15258160260194875.

Abstract

A total of 201 patients with breast cancer, ovarian cancer, or hematological malignancies underwent mobilization of peripheral blood stem cells (PBSC) using chemotherapy and granulocyte-colony stimulating factor (G-CSF). Stem cell products were collected using the Baxter CS3000 pheresis machine. The Baxter Isolex 300i was used to perform 240 CD34(+) cell separations on the apheresis products. Factors affecting yield and purity of the CD34(+) cells were analyzed. Overall yield was 55% and overall purity was 91.7%. T cell contamination was limited to 0.43% of total cells. Variables including red blood cells (RBC) concentration, platelet concentration, CD34(+) cell concentration, total WBCs selected, and time until processing had little effect on yields and purities. Installation of version 2.5 of the software in the Isolex 300i showed a modest improvement in yield and purity. Patients were reinfused with the cryopreserved CD34(+) selected cells following high-dose chemotherapy. No infusion-related side effects were noted. Analysis of engraftment data using the CD34(+)-selected cells revealed an increased risk of delayed or failed platelet engraftment when <5.0 x 10(6) CD34(+) cells per kilogram were transplanted. The Baxter Isolex 300i provides reproducible CD34(+) cell purification over a wide range of starting conditions. To provide prompt engraftment, >5.0 x 10(6) CD34(+) cells per kilogram should be infused for transplantation.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antigens, CD34 / blood*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / therapy
  • Cell Separation / instrumentation*
  • Cell Separation / methods
  • Combined Modality Therapy
  • Female
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Mobilization / methods
  • Hematopoietic Stem Cells / cytology*
  • Humans
  • Leukemia, Myeloid, Acute / therapy
  • Leukocyte Count
  • Lymphoma / therapy
  • Male
  • Middle Aged
  • Multiple Myeloma / therapy
  • Neoplasms / drug therapy
  • Neoplasms / therapy
  • Regression Analysis

Substances

  • Antigens, CD34
  • Antineoplastic Agents